Want to see RANI full AI Analyst Report?
RANI Stock Chart & Stats
$0.85
-$0.04(-4.79%)
At close: 4:00 PM EDT
$0.85
-$0.04(-4.79%)
Day’s Range― - ―
52-Week Range$0.44 - $3.87
Previous Close$0.82
Volume837.84K
Average Volume (3M)910.20K
Market Cap
$105.56M
Enterprise Value$99.74
Total Cash (Recent Filing)$43.40M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding112,389,150
10 Day Avg. Volume1,465,082
30 Day Avg. Volume910,200
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.50Price Target Upside782.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$4.13M
Bulls Say, Bears Say
Bulls Say
Proprietary Oral Biologic Delivery PlatformRani’s ingestible RaniPill platform provides a structural competitive advantage by enabling oral delivery of biologics that otherwise require injections. If clinically validated, the platform creates high barriers to entry, broad therapeutic applicability, and long-term licensing and royalty potential.
Partnership-driven Business ModelRani’s collaboration model (Chugai, ProGen and contract revenues) shifts capital burden to partners, provides milestone and R&D funding, and validates the platform via third‑party sponsors. Durable partner relationships can accelerate clinical programs and create non‑dilutive revenue touchpoints over time.
Liquidity Runway And Recent FinancingReported cash and marketable securities (~$43.4M) plus a May 2026 $20M registered equity placement materially extend runway. This funding supports ongoing clinical activity and milestone execution into late‑2027, reducing immediate financing pressure and allowing focused development and partner engagement.
Bears Say
Minimal And Declining Revenue ScaleTTM revenue is very small and falling, indicating limited commercialization traction. Low revenue scale makes the business highly milestone‑dependent and lumpy, limits absorption of fixed R&D/G&A costs, and heightens execution risk unless partnerships convert into steady commercial receipts.
Sustained Cash BurnOperations continue to consume cash (negative OCF and FCF), so the company remains dependent on external funding to progress trials. Persistent cash burn raises dilution risk, could force reprioritization of programs if financings slip, and constrains long‑term financial flexibility.
Nasdaq Listing Compliance RiskReceiving a Nasdaq bid‑price noncompliance notice is a structural governance/listing risk. Potential delisting or a required reverse split would reduce liquidity, complicate future equity raises, distract management, and could negatively affect partner perceptions and investor access over the medium term.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.44 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $105.56M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 112,389,150 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (782.35% Upside)
$7.50 (782.35% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $5.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
115.04%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
RANI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$7.50
▲(782.35% Upside)
Technical Analysis
Ownership Overview
24.72% Insiders
4.85% Mutual Funds
0.15% Other Institutional Investors
66.16% Public Companies and
Individual Investors